Krystal Biotech (NASDAQ:KRYS) Given “Buy” Rating at Chardan Capital

Chardan Capital reissued their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $212.00 price target on the stock.

Several other brokerages have also recently issued reports on KRYS. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Stifel Nicolaus lifted their price objective on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Citigroup lifted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and an average target price of $206.67.

Krystal Biotech Trading Down 7.3 %

Shares of NASDAQ KRYS opened at $156.64 on Wednesday. The stock has a fifty day simple moving average of $180.70 and a 200-day simple moving average of $185.17. Krystal Biotech has a twelve month low of $107.50 and a twelve month high of $219.34. The stock has a market capitalization of $4.51 billion, a PE ratio of 88.50 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business’s quarterly revenue was up 879.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.67) earnings per share. On average, equities analysts predict that Krystal Biotech will post 2.97 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 14.10% of the stock is currently owned by insiders.

Institutional Trading of Krystal Biotech

Hedge funds and other institutional investors have recently made changes to their positions in the company. Key Financial Inc purchased a new position in Krystal Biotech during the 2nd quarter worth approximately $28,000. Blue Trust Inc. boosted its holdings in shares of Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after acquiring an additional 163 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech during the third quarter worth approximately $40,000. Values First Advisors Inc. acquired a new position in shares of Krystal Biotech in the 3rd quarter valued at $53,000. Finally, Quest Partners LLC purchased a new stake in Krystal Biotech in the 2nd quarter valued at $71,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).